Neoplasms

All Conditions

Digestive System Diseases

Behaviors and Mental Disorders

Carcinoma

Carcinoma, Hepatocellular

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Adenocarcinoma

Liver Neoplasms

Gastrointestinal Neoplasms

Digestive System Neoplasms

Gastrointestinal Diseases

Liver Diseases

Quality of Life

Antineoplastic Agents

All Drugs and Chemicals

Sorafenib

Protein Kinase Inhibitors

Enzyme Inhibitors

Syp Oncoxin 25 ml bd and Cap. Oncoxin bd orally for 180 days

Tab Suranix 200 mg 2 tab bd and Syp Oncoxin 25 ml bd and Cap. Oncoxin bd orally for 180 days

Only supportive treatment. No chemotherapy, radoiotherapy, ablation or surgical intervention will be carried out.

Syp Oncoxin 25 ml bd and Cap. Oncoxin bd for 180 days

Oncoxin

Tab Suranix 200 mg 2 tab bd and Syp Oncoxin 25 ml bd and Cap. Oncoxin bd for 180 days

Suranix

Mamun A Mahtab, MD, FACG

Helal Uddin, BSc

Lovely Begum, BPharm

Oncoxin in combination with Surafenib is safe and results in improved survival in patients with hepatocellular carcinoma (HCC)

To assess therapeutic efficacy and safety of Oncoxin plus Surafenib in hepatocellular carcinoma

To see if there is reduction in serum alpha fetoprotein level in hepatocellular carcinoma patients after administration of Oncoxin plus Surafenib

To see if there is reduction tumor size and or number in hepatocellular carcinoma patients after administration of Oncoxin plus Surafenib

To see if there is improvement of quality of life in hepatocellular carcinoma patients after administration of Oncoxin plus Surafenib

To see if there is improved survival in hepatocellular carcinoma patients after administration of Oncoxin plus Surafenib

Safety and Efficacy of Oncoxin Plus Surafineb in Hepatocellular Carcinoma

Study to Evaluate Safety and Therapeutic Efficacy of a Combination Therapy of 'Oncoxin', a Nutritional Supplement and Surafenib, a Multikinase Inhibitor in Patients With Hepatocellular Carcinoma

To study the number of participants who have prolonged survival in months after receiving Oncoxin plus Surafenib for 24 weeks

To see whether Oncoxin plus Surafenib results in reduction in serum alpha-fetoprotein level in ng/ml and decrease in tumor size in mm in hepatocellular carcinoma patients off treatment for 24 weeks, after receiving Oncoxin plus Surafenib for 24 weeks.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Safety and Efficacy of Oncoxin Plus Surafineb in Hepatocellular Carcinoma	NCT01747642	Quality of Life	Oncoxin Suranix	18 Years - 70 Years	Clinical Research Organization, Dhaka, Bangladesh
Safety and Efficacy of Oncoxin Plus Surafineb in Hepatocellular Carcinoma	NCT01747642	Quality of Life	Oncoxin Suranix	18 Years - 70 Years	Clinical Research Organization, Dhaka, Bangladesh

Spots Global Cancer Trial Database for surafenib

Every month we try and update this database with for surafenib cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for surafenib

Every month we try and update this database with for surafenib cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for surafenib cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.